ACAD NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

ACADIA Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 25.87 USD
4.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is 11.2% above the Trend Line and sits at 71.4% of its 52-week range. The latest completed week returned 4.1%, after a -0.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bullish with 45/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 47 out of 100
Latest Close 25.87 USD 31 Jul 2026
1W Return 4.1% latest completed week
4W Return -0.4% short-term follow-through
12W Return 15.5% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Next-week expectancy is negative at 40.42% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.1% Latest completed week; four-week move -0.4%. Indicator stack 28/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.42% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 45/100 conviction; expected move 9.9%. News sentiment 59/100 56 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 11.2% above the Trend Line and sits at 71.4% of its 52-week range. The latest completed week returned 4.1%, after a -0.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4912-week average 0.20

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.49Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.4% over four weeks, 15.5% over 12 weeks, and 9.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.1%
4W-0.4%
12W15.5%
26W2.9%
52W9.9%
Active trend streak0 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.00Latest activity-pressure read.
Pressure change64.4%Four-week change in activity pressure.
Leadership-0.37Latest relative-leadership reading.
RS change91.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength19/100Blend of value, momentum, and quality. Underlying universe rank 82; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality84/100Profitability and accounting quality. Underlying universe rank 17; rank 1 is best.
Momentum32/100Medium-term price momentum. Underlying universe rank 69; rank 1 is best.
Growth86/100Revenue and earnings growth. Underlying universe rank 15; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework21/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
11.3x
Price divided by trailing earnings.
Price / sales
3.9x
Market value relative to trailing revenue.
EV / EBITDA
31.7x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
5.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
91.5%
Gross profit retained from each unit of revenue.
Operating margin
10.5%
Operating profit retained from revenue.
Free-cash-flow margin
21.1%
Free cash flow generated from revenue.
Return on invested capital
8.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
9.9%
Latest one-year revenue growth.
EPS growth
64.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-6.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.2%
Net share repurchases relative to market value.
Shareholder yield
-1.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ACAD shows bullish options pressure with a 45/100 conviction score, put-call volume ratio of 0.28, expected move of 9.9%, and Sharemaestro trend signal inactive.

Conviction45/100
Expected move9.9%
Put/call volume0.28
Pressure66
Speculation45
Volatility72
Trend agreement0
Open options detail
Insider activity15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment59/100

Weighted news tone is neutral across 56 relevant articles.

23 positive · 30 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move9.9%Nearest-chain priced movement where available.
52-week drawdown-8.7%Distance below the 52-week high.
13-week volatility5.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+17.1%Week of 26 Jun.
Worst week-9.8%Week of 6 Mar.
Latest week+4.1%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains9
Flat weeks0
Modest losses8
Sharp losses5
Recent vol5.2%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.9% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape44/100

Trend, activity pressure, participation, and risk combine to a 44/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.49; No reversal markers Next-Week ExpectancyNegative 40.42%

Next-week expectancy is negative with a 40.42% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors36/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 77; Small Cap Core rank 91 SVQF21/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 572.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

ACAD shows bullish options pressure with a 45/100 conviction score, put-call volume ratio of 0.28, expected move of 9.9%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 9.9% Sentiment59/100

Weighted news tone is neutral across 56 relevant articles.

Acadia Pharmaceuticals EVP Thompson sells $432,662 in stock By Investing.com Insiders15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202625.87 USD4.1%23.26 USD21.17 USD1.00-0.376.9MOff
24 Jul 202624.84 USD-3.0%23.27 USD21.18 USD1.02-4.066.3MOff
17 Jul 202625.60 USD-2.4%23.37 USD21.21 USD1.15-2.957.5MOff
10 Jul 202626.22 USD1.0%23.42 USD21.24 USD0.95-4.907.6MOff
3 Jul 202625.97 USD2.6%23.45 USD21.28 USD0.61-4.196.8MOff
26 Jun 202625.32 USD17.1%23.50 USD21.27 USD0.25-5.8513.7MOff
19 Jun 202621.62 USD2.5%23.49 USD21.26 USD-0.17-23.407.0MOff
12 Jun 202621.09 USD-2.2%23.55 USD21.28 USD-0.31-23.834.9MOff
5 Jun 202621.56 USD-0.5%23.65 USD21.30 USD-0.36-20.815.6MOff
29 May 202621.66 USD2.7%23.69 USD21.32 USD-0.28-24.444.8MOff
22 May 202621.10 USD-1.4%23.72 USD21.34 USD-0.38-24.738.4MOff
15 May 202621.40 USD-4.5%23.75 USD21.36 USD-0.52-23.257.9MOff
8 May 202622.40 USD2.1%23.73 USD21.38 USD-0.50-20.4212.3MOff
1 May 202621.95 USD-0.0%23.66 USD21.37 USD-0.73-17.916.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.